Page 1,109«..1020..1,1081,1091,1101,111..1,1201,130..»

‘His legacy lives on’: Grandmother who helped create newborn screening law tells history of bill – News-Leader

Posted: March 6, 2020 at 12:41 am

Buy Photo

Two-year-old Regann Moore lights up as she watches videos on her iPad at home on Thursday, Feb. 20, 2020. Moore has a rare disease known as Krabbe Disease and received a life-saving stem cell donation less than a month after being born.(Photo: Nathan Papes/Springfield News-Leader)

Soon after the News-Leader published a story about 2-year-old Regann Moore,a Springfield child whose life was saved thanks to a newborn screening test, someone tweeted the story toMissouri State Rep. Becky Ruth.

"I bawled my eyes out," Ruth said. "I just cried."

She cried because she knew Regann is alive thanks to the death of Ruth's grandson, Brady.

"I cry and smile when I see these children," Ruth said. "We are always so thankful. For us, we see Brady's death wasn't in vain. His legacy lives on by helping save the lives of other children."

More: Springfield child with rare, deadly disease continues to amaze doctors, family

Regann, who is 2 now, was diagnosed right after she was born withKrabbe Disease, a rare metabolic disorder that must be diagnosed at birth and treated as soon as possible with a stem cell donation.

The newborn screening is important because babies with Krabbe Disease appear healthy at birth. Signs something is wrong usually don't appear until it's too late for treatment to be effective.

That is what happened to Brady in 2009. He wasn't diagnosed with the disease until he was 4.5 months old too late for treatment.

Brady died 10 days before his first birthday.

Brady Cunningham died of Krabbe Disease just before his first birthday.(Photo: Courtesy of the Cunningham family)

That's why Ruth and her family fought to get lawmakers on board with making sure all newborns in Missouri are screened for Krabbe Disease.

TheBrady Alan Cunningham Newborn Screening Act was passed in 2009 and screening began in 2012. Ruthsaid her family was OK with the three-year lag because they realized the lab needed time to become equipped to test for the disease.

Missouri is one of just a few states that do the newborn screening.

Brady's law also includes screening for Pompe, Fabry, Gauche and Niemann-Pick diseases. Since then, SCID, MPS I, MPS II and SMA diseases are screened, as well.

Ruth became a state representative in 2015and said newborn screening is her passion.

Her experience with getting Brady's law passed is what led her to seek office.

"It showed me what just a regular everyday person can do and what a differenceyou can make," Ruth said. "People a lot of times complain about politicians and the legislature, but we also do very good things here."

Ruth said her family knows of another child with Krabbe Disease who was saved thanks to newborn screening and a stem cell transplant.

That child is now 4. Ruth said her family and that child's family have a "strong connection."Ruth said shehopes to someday meet Regann's family.

Brady Cunningham was born in 2008. His family is from Campbell in southeast Missouri.

Bradyappeared healthy at birth and was not tested for Krabbe Disease.

Ruth said he started having health problems after about a month and a half. Brady went through "a myriad of diagnoses," Ruth recalled, including acid reflux and seizures.

"Finally my daughter took him to Children's Hospital in St. Louis," she said. "They promised her he wouldn't leave without a diagnosis."

Missouri State Rep. Becky Ruth was moved to tears after reading about Regann Moore, a Springfield child whose life was saved thanks to newborn screening for Krabbe Disease. Ruth and her family encouraged Missouri lawmakers to make sure all Missouri babies are tested for the deadly disease after her grandson, Brady, died from it.(Photo: Submitted by Becky Ruth)

Three weeks later, Brady was diagnosed with Krabbe Disease, which rapidly destroys the nervous system.

"We were told there was nothing they could do," she said. "It was one of the worst days of all of our lives."

Brady was 4.5 months old when he was diagnosed. In order for a stem cell donation to have any chance of being effective, babies must have the transplant within the first month of their life.

Regann, the Springfield child, was given a stem cell donation thanks to an umbilical cord donation.

Thediseaseaffects about one in every 100,000 people in the United States.

"They are missing an enzyme that helps keep their nervous system intact," said Dr. Shalini Shenoy, Regann's transplant doctor. "Because this is missing, they have degeneration of the brain and nervous system. And if you let it progress, it is fatal very early."

Without the stem cell donation, babies die within the first few months, Shenoy said.

"You can't change someone's genetic makeup," Shenoy said. "But when you put stem cells into their bone marrow from somebody else who is normal, some of these cells migrate into their brain and into their nervous system and supply what they are lacking themselves."

It takes some time for the transplant to begin working for the transplanted cells to "settle down" and begin making the missing enzyme, Shenoy said.

"Because of that, the earlier you transplant a Krabbe patient, the more you will be able to rescue them," she said. "You want to catch them before too much damage is done. Once there's a lot of nerve damage, it's not reversible. If I saw a Krabbe patient two months after they were born or four months after they were born when they already had major problems, it's unlikely I'd be able to rescue them too much."

Since the screening and the stem cell transplant treatment are both relatively recent medical advancements, Shenoy said it's anybody's guess what the future will hold for children who, like Regann, were successfully treated with a stem cell transplant early on.

Ferrell Moore holds his two-year-old daughter Regann Moore at their home on Thursday, Feb. 20, 2020. Regann has a rare disease known as Krabbe Disease and received a life-saving stem cell donation less than a month after being born.(Photo: Nathan Papes/Springfield News-Leader)

Regann can't stand on her own or walk yet. But her family is determined to make that happen. She cannot talk but is learning sign language to communicate.

She has regular visits with speech and occupational therapists.

Regann's dad Ferrell Moore got to take her to the circus recently, something the little girl seemed to enjoy.

"She is the joy of my life," Ferrell Moore said. "When I come home, it couldn't be any better to see her and how happy she is to see me."

Read or Share this story: https://www.news-leader.com/story/news/local/ozarks/2020/03/05/grandma-who-helped-pass-newborn-screening-law-tells-story-bill/4954655002/

Continue reading here:
'His legacy lives on': Grandmother who helped create newborn screening law tells history of bill - News-Leader

Posted in Stem Cell Videos | Comments Off on ‘His legacy lives on’: Grandmother who helped create newborn screening law tells history of bill – News-Leader

Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders – Yahoo Finance

Posted: March 4, 2020 at 10:49 pm

LEXINGTON, MA / ACCESSWIRE / March 4, 2020 / Keros Therapeutics, Inc., a biotechnology company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need, today announced the close of its $56 million Series C financing, bringing its total venture funding to $78.5 million to date. The Series C financing was led by new investors Foresite Capital, OrbiMed, Cowen Healthcare Investments and Venrock. Certain of Keros' existing investors also participated including Pontifax, Arkin Bio Ventures, Partners Innovation Fund, Global Health Sciences Fund and Medison Pharma.

As part of the Series C financing, Nima Farzan, MBA, an experienced biopharmaceutical executive, and Carl Gordon, Ph.D., CFA, Managing Partner at OrbiMed, will be joining the Board of Directors of Keros.

Proceeds from this financing will be used to advance Keros's pipeline of product candidates through multiple clinical data readouts. KER-050, our lead clinical-stage protein therapeutic product candidate, is currently being developed to correct cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. KER-047, our lead clinical-stage small molecule product candidate, is being developed for treatment of anemias resulting from high hepcidin levels and for fibrodysplasia ossificans progressiva, or FOP, a rare genetic disease where muscle and connective tissues gradually become replaced by bone.

"The Keros team has a deep understanding of the biology relevant to the role of members of the TGF- family of proteins in the development of blood cells, muscle and bone, and we have leveraged that knowledge to advance two product candidates through Phase 1 clinical trials," said Jasbir S. Seehra, Ph.D., President and CEO of Keros. "This additional funding will allow us to rapidly advance our lead programs through Phase 2 clinical trials to provide proof-of-concept for novel treatments that could potentially address the limitations of current therapeutic approaches in diseases linked to the dysfunction of TGF- signaling pathways."

"We are excited to lead this important financing to advance Keros's lead programs through Phase 2 proof-of-concept studies. We believe Jas and his team are world leaders in the field TGF- biology," said Jim Tananbaum, CEO and Managing Director of Foresite Capital.

"We are thrilled to welcome these highly respected investors and look forward to working with our newest Board members", said Ran Nussbaum, Managing Partner of Pontifax and Chairman of the Keros Board of Directors. "With this financing, Keros is in a strong position to advance its technology centered on the role of members of the TGF- family of proteins and bring new treatments to patients suffering from hematologic and musculoskeletal disorders."

Our Biological Focus

Keros focuses on the role of members of the TGF- family of proteins in the development of blood cells, muscle and bone. Aged and damaged cells are routinely replaced by new cells in normally functioning organs. These new cells are derived from stem cells that have the ability to differentiate into cells with specialized function when appropriate signals are provided to maintain the homeostatic state of the tissue. Members of the TGF- family of proteins, including activins and bone morphogenetic proteins, provide the necessary signals for this process of self-renewal and repair.

Product Candidates

Our lead, clinical-stage protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF- receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF- family of proteins to promote hematopoiesis, and is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS, and in patients with myelofibrosis.

Our lead, clinical-stage small molecule product candidate, KER-047, is designed to selectively and potently inhibit activin receptor-like kinase-2, or ALK2, a TGF- receptor. We believe that KER-047 has the potential to ameliorate excessive ALK2 signaling, and Keros is developing KER-047 for the treatment of anemia resulting from high hepcidin levels as a direct consequence of elevated ALK2 signaling, including our initial target, iron-refractory iron deficiency anemia, or IRIDA. We are also developing KER-047 as a treatment for FOP, a rare genetic disease resulting from mutations in the ALK2 receptor.

Story continues

About Keros Therapeutics

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. We are a leader in understanding the role of the Transforming Growth Factor-Beta family of proteins that is a master regulator of red blood cell and platelet production as well as the growth, repair and maintenance of muscle and bone. Our lead protein therapeutic product candidate, KER-050, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. Our lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. For more information on Keros Therapeutics, visit http://www.kerostx.com

Keros Therapeutics Investor Contacts:

Julia Balanovajbalanova@soleburytrout.com646 378 2936

SOURCE: Keros Therapeutics

View source version on accesswire.com: https://www.accesswire.com/579058/Keros-Therapeutics-Closes-56-Million-Series-C-Financing-to-Advance-its-Programs-in-Hematologic-and-Musculoskeletal-Disorders

Go here to see the original:
Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders - Yahoo Finance

Posted in Stem Cell Treatments | Comments Off on Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders – Yahoo Finance

Asking for Help is a Sign of Strength, Not of Weakness – Thrive Global

Posted: March 4, 2020 at 10:49 pm

When I got off the phone with the National President of the Hadassah, the worlds largest Zionist womens organization who had called to invite me to serve on the board of this amazing nonprofit, I was filled with a sense of resolve, renewal and responsibility I was also a bit overwhelmed.

Of course, I knew about the work of Hadassah the creation of two hospitals in Jerusalem, Israel, that were known as bridges to peace in the Middle East and were world-famous for their medical miracles, like stem cell treatments that reversed the effects of MS, and I was eager for my first board meeting. Id served on other boards and I thought I was experienced enough for my new role, but I quickly realized that to truly be effective and not to feel like deadwood on a board, which I detested from my days as a director of a nonprofit, I couldnt go it alone.

Its taken me many years (and many failures) to realize that asking for help is a sign of strength, not of weakness. I wish I could go back in time and convince my younger self this.

Id never had a mentor. Maybe because it didnt occur to me in my youthful ignorance that I needed one, but more likely because as a professional in a male-dominated field, no one had ever offered or felt particularly approachable. The corporate culture I was most familiar with was sink or swim and youd better do it quickly and youd better be tough.

Fortunately for me, by the time I was mature enough to realize I would benefit from a mentor, I was already a dedicated volunteer with my local Hadassah chapter. I was surrounded by smart, compassionate, accomplished women who were typically twenty years my senior. These women were not interested in taking me down but in lifting me up.

One of these women was also on the Hadassah National Board Liz Alpert. Liz is whip-smart, bold, adventurous and to my delight, lots of fun. Liz is also generous with sharing her time with me. Because of Lizs decades of Hadassah national leadership, Liz was like my personal encyclopedia of Hadassah. She could fill in the blanks, read between the lines and give me the historical perspective that wasnt possible to glean no matter how thoroughly I would prepare for the board meetings. Sometimes we disagreed on matters, but I always respected her well-reasoned opinion.

Somewhere between meetings and conferences, Liz and I became great friends. We recently led a Fashion, Food, Wine & Design travel tour to Israel, where I depended on Lizs detail-oriented personality more times than I can count. Weve had fun together at Hadassah conferences across the U.S. and I discovered from our walks and talks along the beach in Santa Cruz that Liz has more hustle than Ill ever have.

Recently, Liz and I found ourselves early on a beautiful day in Oakland, walking around Lake Merritt (well, Liz was walking, I was perpetually hurrying to catch up to her). The lake was like a mirror and particularly tempting as we rounded past the boathouse. Lets rent a rowboat! I said, Liz asked if Id rowed before. Yes, I replied, and off we went. In the middle of the lake after Id lost the oar (yet again) Liz realized that she should have asked me not whether Id done this before, but whether I knew how to row, which I did not. Of course, Liz knew how to row from a childhood summer camps. Liz spent the rest of the morning patiently coaching me and taught me how to row (at least well enough to get back to the dock).

I think the rowboat adventure (or misadventure, depending who you ask) is a good analogy for our mentor/mentee relationship. I had the passion, but I didnt know what I didnt know. Luckily, Liz was there to teach me how to safely navigate.

Our mentoring relationship is a wonderful mlange of mother-daughter, sisters and friends. Its women supporting and nurturing women with love and wisdom and it creates a family bond without biology. I have experienced this in one other area of my life, with Sammie.

Sammie Rogers came into my life as a teenager when I became her quasi-foster mother and over the years we too have evolved into this same wonderful mlange. It seems that the key to creating this is for both partners to be open and take a leap of faith. Without the competitiveness of a work environment or the invariable drama involved in mother-daughter relationships, something special but unnamed is created.

I can offer to help Sammie navigate lifes challenges without the subtext of the frequent mother-daughter condemnation and hurt feelings. And Sammie offers me love and inclusion that helps fill my heart. Its a wonderful feeling as a mentor to root for your mentee and celebrate in her successes and in the way she confronts lifes challenges and loss and to watch her persevere and thrive.

Mentoring is a celebration of strength of both the mentee and the mentor and of the bond with them. While I am confident in Sammies strength and perseverance, she is confident in mine and we rely on each other. I brought Sammie to Israel for a vacation, but she brought me up to the top of Masada to see the sun rise. She led the way, she encouraged me, she stayed with me while I caught my breath. Neither of us could accomplish what we did without the other and we had fun doing it and such a sense of renewal, resolve and responsibility.And thats what mentoring brings to both partners.

Read more here:
Asking for Help is a Sign of Strength, Not of Weakness - Thrive Global

Posted in Stem Cell Treatments | Comments Off on Asking for Help is a Sign of Strength, Not of Weakness – Thrive Global

Maryland Stem Cell Center Consortium & Core Facility …

Posted: March 4, 2020 at 10:48 pm

In order to take advantage of the potential of stem cells for the purposes of regenerative medicine, robust standardized methods are required to generate sufficient quantities of stem cells that meet defined criteria for specific stem/progenitor cell populations.

Currently, the availability of these cells for research, drug screening and therapeutic use is limited due to technical challenges associated with their generation and expansion. On May 3, 2011, The University of Maryland School of Medicines Center for Stem Cell Biology and Regenerative Medicine and Paragon Bioservices, Inc., a contract research and GMP manufacturing company, received a Biotechnology Shared Resource Award from the state of Maryland to establish The Maryland Stem Cell Consortium to facilitate the research, commercial development and clinical application of stem cell based technologies and therapies. A key component of the consortium is the establishment of a stem cell core facility that has expertise to expand and differentiate induced pluripotent stem cells, mesenchymal stem cells, and other types of stem cells for laboratory and clinical research under GLP/GMP conditions, as needed. This core facility is open to all, without intellectual property reach-through. Cell banking and genetic modification of stem cells is also available. The core services are available on a fee-for-service model that is open to the wider stem cell community, public and private, especially in the state of Maryland. Life Technologies, Inc., a global biotechnology company that is a provider of scientific products and reagents, is also participating in the consortium and providing training opportunities for research scientists.

As a founding member of the consortium, the University of Maryland School of Medicine Center for Stem Cell Biology & Regenerative Medicine is committed to developing strong interactions between academia and the private sector and seeks to facilitate the partnering of faculty expertise with that of the external private and public sectors. The Center faculty are interested in the analysis of molecular pathways regulating basic stem cell biology, characterization of stem and progenitor cell properties to improve expansion of stem cells for transplantation, optimization of directed differentiation of pluripotent cells into distinct cell lineages, functional characterization of differentiated cells and testing the translational potential of stem cell and their progeny. Taking advantage of patient material from the University of Maryland Hospital System (a network of 12 hospitals centered at the adjacent ~1000-bed University of Maryland Medical Center plus the Baltimore Veterans Administration Hospital), Center faculty are establishing induced pluripotent stem models for human disease, such as Gauchers Disease. The Centers researchers are also using mesenchymal stem cells for repair of a range of tissue types; and several of our cardiologists and cardiac surgeons are involved in clinical trials to test stem cell-mediated cardiac repair. Via the Maryland Stem Cell Consortium, we hope to encourage productive scientific and intellectual interactions between researchers in academia, government and private sectors to accelerate stem cell related discoveries and their translation into much-needed treatments.

If you would like more information about the Maryland Stem Cell Consortium or are interested in participating, please contact the Center.

More:
Maryland Stem Cell Center Consortium & Core Facility ...

Posted in Maryland Stem Cells | Comments Off on Maryland Stem Cell Center Consortium & Core Facility …

Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery – Science Magazine

Posted: March 4, 2020 at 10:48 pm

Various in vitro cell culture assays have been used for decades to evaluate disease pathology and uncover potential therapeutic treatments. Despite many successes with these models, they have critical shortcomings. Growing evidence suggests that models providing more predictive and translational observations are desperately needed. Researchers are now moving from reductionist, 2D monoculture assay models to more complex 3D cell models, such as organoids and induced pluripotent stem cell (iPSC) cultures, in order to better evaluate the dynamic interactions between cells in an environment more closely emulating that of the in vivo milieu, and to assess patient-specific phenotypic effects following drug treatment. Effective, well-characterized, advanced cell models hold promise for improving our understanding of disease pathology and progression, and are critical for the identification of novel therapeutic targets.

During this roundtable webinar, the speakers will:

This webinar will last for approximately 60 minutes.

STEMCELL TechnologiesCambridge, UK

Dr. Simmini is an R&D scientist in the gastrointestinal biology group at STEMCELL Technologies. His group focuses on developing products that support the generation of 3D gastrointestinal organoid cultures both from human primary tissue and human induced pluripotent stem cells. Prior to joining STEMCELL Technologies in 2016, he obtained his Ph.D. in stem cells, developmental biology, and cancer at the University of Utrecht in The Netherlands. During that time, he conducted research with the group of Jacqueline Deschamps at the Hubrecht Institute in Utrecht, where he investigated the molecular mechanisms controlled by transcription factor CDX2 in adult mouse intestinal stem cells and during embryonic development. In 2015, he began postdoctoral research, joining the group of Jan Paul Medema and Louis Vermeulen at the Amsterdam Medical Centre in Amsterdam, where he investigated mechanisms regulating intestinal stem cell proliferation and differentiation in colorectal cancer. He is currently involved in several Horizon 2020 European Research Council projects in different roles: researcher within the INTENS (INtestinal Tissue ENgineering Solution) consortium; partner in the SINERGIA (Advanced technologieS for drug dIscovery and precisioN mEdicine: in vitRo modellinG human physiology and diseAse) project; and supervisor and member of the executive board of the Organovir-ETN (Organoids for Virus Research-European Training Network) grant.

Wellcome Sanger InstituteCambridge, UK

As a staff scientist at the Wellcome Sanger Institute, Dr.Hale undertakes basic research projects into hostbacterial interactions while also teaching relevant skills to students and visiting scientists. Her projects include growing and differentiating human induced pluripotent stem cells to either a macrophage-like lineage or as intestinal 3D organoids, then utilizing them to investigate pathogen interactions. The main techniques used are flow cytometry, confocal imaging, high-throughput Cellomics assays, Luminex cytokine assays, and cell culture. The pathogens have varied over the years, but have included Salmonella, Klebsiella, enteropathogenic Escherichia coli (EPEC), Chlamydia, and Leishmania.

UK Dementia Research InstituteCambridge, UK

Dr. Avezov received his Ph.D. in cell research and immunology from the George S. Wise Faculty of Life Sciences at Tel Aviv University in 2010. He conducted his postdoctoral work at the University of Cambridge Wellcome-MRC Institute of Metabolic Science and the Cambridge Institute for Medical Research until 2017 with David Ron, FRS. Quantitative cell biology in the context of human disease has been at the core of Dr. Avezovs research. Working at the interface of biomedical research, physics, and mathematical sciences, he developed the cross-disciplinary expertise for probing intracellular chemical and physical processes in real time. This enabled discoveries of unexpected features of the endoplasmic reticulum (ER), such as an active ER luminal transport mechanism. These findings provide insights into the roles of the ER and its morpho-regulation in neuronal (patho)physiology. Dr. Avezov is currently a UK Dementia Research Institute Group Leader running an interdisciplinary program that seeks to understand early contributions of fundamental cellular processes ranging from ER transport to neurodegeneration.

Science/AAASWashington, D.C.

Dr. Oberst did her undergraduate training at the University of Maryland, College Park, and her Ph.D. in Tumor Biology at Georgetown University, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine, the Howard Hughes Medical Institute, The Endocrine Society, and the National Institutes of Mental Health.

Original post:
Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery - Science Magazine

Posted in Maryland Stem Cells | Comments Off on Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery – Science Magazine

With Over 280 Therapies Under Evaluation, the Stem Cell Therapy Market is Estimated to be Worth USD 8.5 Billion by 2030, Claims Roots Analysis – P&T…

Posted: March 4, 2020 at 10:46 pm

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

LONDON, March 4, 2020 /PRNewswire/ -- Roots Analysishas announced the addition of "Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))" report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic products

More than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cells

It is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regions

Within these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015

More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domain

Presently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030

The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.htmlor email sales@rootsanalysis.com

You may also be interested in the following titles:

Contact:Gaurav Chaudhary+1(415)800-3415+44(122)391-1091Gaurav.Chaudhary@rootsanalysis.com

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

Read the original:
With Over 280 Therapies Under Evaluation, the Stem Cell Therapy Market is Estimated to be Worth USD 8.5 Billion by 2030, Claims Roots Analysis - P&T...

Posted in Cell Therapy | Comments Off on With Over 280 Therapies Under Evaluation, the Stem Cell Therapy Market is Estimated to be Worth USD 8.5 Billion by 2030, Claims Roots Analysis – P&T…

Ori biotech adds traceability to cell therapy platform – Bioprocess Insider – BioProcess Insider

Posted: March 4, 2020 at 10:46 pm

Ori Biotech has partnered with software firm TrakCel to add supply chain monitoring technology to its cell and gene therapy manufacturing system.

The non-exclusive deal financial terms of which were not disclosed will allow cell and gene therapy developers and contract development and manufacturing organizations (CDMOs) that use the Ori platform to monitor manufacturing processes in real-time using Trakcels technologies.

The firms plan to develop suitable points of integration in order for a shared data platform to be available to partners.

Image: iStock/angelp

Ori co-founder and CSO Farlan Veraitch said, The integration of TrakCels advanced therapy supply chain tracking software with the Ori full-stack platform is another step forward enabling our customers to have full visibility throughout the supply chain.

This was echoed by Fiona Withey, co-founder and CEO, TrakCel.

She said, Closed system manufacturing is becoming progressively more important for the ongoing future of the cell and gene therapy sector, and we look forward to working with Ori to offer more integrated solutions to the wider industry.

Oris technology is an automated, closed cell process system composed of a scalable bioreactor and fluid handling platform.

The platform is designed to help developers reduce the time and cost involved in making autologous cell therapies according to CEO Jason C. Foster who spoke with Bioprocess Insider in January.

The deal with Trakcel comes after a busy period for Ori.

In early January firm completed a $9.4M (7M) Seed Round with backers including Amadeus Capital Partners, Delin Ventures and Kindred Capital. At the time Ori said it would use the proceeds to bring its manufacturing platform to market.

A few weeks later Ori announced it had partnered with Hitachi Chemical Advanced Therapeutics Solutions (HCATS), the contract development and manufacturing organization (CDMO) subsidiary of Hitachi Chemical Company.

The deal covered the development and commercialization of technology solutions specific to the cell and gene therapy industry.

Ori told us The first external tests of the Ori platform begin in March 2020 with our CDMO partner, HCATS, and our two therapeutics developer partners.

Read more: Ori: Partnerships key to bring down cell therapy COGS

Read the original post:
Ori biotech adds traceability to cell therapy platform - Bioprocess Insider - BioProcess Insider

Posted in Cell Therapy | Comments Off on Ori biotech adds traceability to cell therapy platform – Bioprocess Insider – BioProcess Insider

Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference – Yahoo Finance

Posted: March 4, 2020 at 10:46 pm

SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will present at the 9th Annual LEERINK Partners Global Healthcare Conference (Lotte New York Palace Hotel, New York) on Thursday Feb 27 at 11:00-11:25 AM (Presentation Room Adams).

Key updates:

DAR-T specific developments:

Sorrentos proprietary DAR structure offers potential advantages over the conventional CAR (chimeric antigen receptor) structure by:

In addition to the proprietary DAR structure, Sorrentos proprietary non-viral knockout-knockin (KOKI) manufacturing approach offers several potential benefits over virus-based transduction currently used for CAR-T therapies:

Combining those approaches, the allogeneic DAR-T products could potentially have the following major advantages over current autologous CAR-T therapy technologies:

Beyond targeting cancer related indications, which is the primary focus of Sorrentos immuno-oncology business, Sorrento believes it can apply its KOKI DAR-T platform against pandemic infectious pathogens, including but not limited to coronaviruses, HBV, HIV, malaria, measles and fungi.

The potential spread of the COVID-19 coronavirus from Wuhan, China is only one example of how quickly a local infection can become a pandemic. Sorrentos agile KOKI DAR-T and DAR-NK cell therapy platforms, coupled with in-house cGMP manufacturing facilities, should allow for emergency adoptive T cell and innate NK cell therapies being produced rapidly for clinical testing.

COVID_DAR_001 has been added to the Sorrento development pipeline and allocated internal priority both to demonstrate the maturity, agility and development readiness of the proprietary platform and to address an emergency and potentially critical patient need in the upcoming months.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical stage immuno-cellular therapies (CAR-T), development stage DAR-T cell therapies, intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and clinical stage oncolytic virus (Sephrevir).

Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin (RTX) and ZTlido. Resiniferatoxin is completing a Phase 1b trial for intractable pain associated with cancer and a Phase 1b trial in osteoarthritis (OA) patients. ZTlido was approved by the FDA on February 28, 2018.

For more information visit http://www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and product candidates, including, but, not limited to, resiniferatoxin (RTX) and DAR-T, the clinical potential of RTX, potential advantages of Sorrentos DAR-T program and NK and CAR gene editing technologies, potential benefits of the KOKI manufacturing approach, potential advantages of allogeneic DAR-T products over current autologous CAR-T therapy and potential applications for the KOKI DAR-T and DAR-NK platforms. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries' technologies and prospects, including, but not limited to, RTX, DAR-T, KOKI and DAR-NK; risks related to seeking regulatory approvals and conducting and obtaining results of clinical trials, including, but not limited to, the Phase 1b studies and any prior RTX studies in animals; costs associated with clinical trials, the clinical and commercial success of RTX; the viability and success of using RTX for treatments in certain therapeutic areas, including for the treatment of intractable pain associated with cancer, Sorrentos DAR-T, KOKI and DAR-NK programs and drug products; risks related to seeking regulatory approvals and conducting clinical trials and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Story continues

Media and Investor Relations

Contact: Alexis Nahama, SVP Corp Development

Telephone: 1.858.203.4120

Email: mediarelations@sorrentotherapeutics.com

Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

ZTlido and G-MAB are trademarks owned by Scilex Pharmaceuticals, Inc. and Sorrento, respectively.

Seprehvir, is a registered trademark of VirttuBiologics Limited, a wholly owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc.

All other trademarks are the property of their respective owners.

2020 Sorrento Therapeutics, Inc. All Rights Reserved.

Read more here:
Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference - Yahoo Finance

Posted in Cell Therapy | Comments Off on Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference – Yahoo Finance

CAR T Cell Therapy Where and How to Access the Lifesaving Living Drug – SurvivorNet

Posted: March 4, 2020 at 10:46 pm

Theres a rapid expansion going on in CAR T cell therapy, the remarkable living drug treatment that involves genetically engineering a patients own immune cells to fight cancer.

As of right now, CAR T cell therapy is approved by the U.S. Food and Drug Administration (FDA) for widespread use in:

Despite there only being two official CAR T cell approvals, however, Dr. Sid Ganguly, Deputy Director of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, tells SurvivorNet that there are many more cancers expected to benefit from the treatment going forward.

You will be seeing many more diseases where the CAR T will become commercially available, Dr. Ganguly says, adding that patients with cancers that do not fall into the two FDA approval categories may still be able to access the treatment by enrolling in clinical trials.

Multiple myeloma is on of these diseases, as MD Andersons Robert Orlowski has previously told SurvivorNet.

Clinical trials which the FDA requires before it can approve a treatment are abundant in CAR T cell therapy. At Dr. Gangulys cancer center alone, he shares that at this moment there are 38 different trials taking place.

Because CAR T cell therapy is a highly specialized, intense procedure, its important to discuss the possibility of a referral with your oncologist.

When a patient is diagnosed with difficult-to-control lymphoma [for example], they should be referred to a center that is equipped with cellular therapeutics and technology, Dr. Ganguly says, adding that, right now at least, most of these specialized centers are located at academic institutions.

If your oncologist gives you a referral to one of these specialized centers, you will then meet with a cellular therapeutics specialist to discuss the next steps.

CAR T cell therapy is a highly technical treatment that carries the risk of several serious side effects, which explains why it requires a team of specialized professionals to administer.

Id say a village is required to take care of one patient [undergoing CAR T cell therapy], Dr. Ganguly says, adding that in his own institution, this village or team of specialists is collectively referred to as a CAR T hub. The team of specialists includes, among others:

So its a big team approach where holistically we take care of the patients and we take them through the whole process of identification to insurance approval trial accrual, collection of the cells, Dr. Ganguly says. And then post-treatment, taking care of the patient is also vitally important.

Originally, Dr. Ganguly says, there were only 16 centers in the country that had the expertise and experience to administer CAR T cell therapy. Now, however, that number is expanding.

With the explosion of CAR T, more and more centers are now involved in cellular therapeutics, he says. But we have a lot of work to do. There are a lot of patients that could benefit from this novel, exciting technology. But the knowledge is very important.

The knowledge that Dr. Ganguly references meaning the awareness that CAR T cell therapy is even an option in the first place, and the know-how needed to find a center offering it is not always a given. Thats why specialists are working hard to bring this knowledge to community oncologists.

We need to go to the grassroots, he says. We need to go to community oncologists and educate and talk about this technology so that the patients who are in dire need of this technique should be promptly referred.

The types of cancers that can benefit from CAR T cell therapy are often aggressive, fast-growing cancers, making it extremely important that oncologists refer their patients promptly in the cases where CAR T cell therapy is an option.

These cancers dont wait, Dr. Ganguly says. They grow exponentially, and sometimes, if we cannot get them on time, then the CAR T cannot be manufactured, and valuable time may be lost.

The importance of timing with CAR T cell therapy occasionally prompts patients to consider the option even before they need it, so that if and when they do need it, they will have access right away.

Sometimes, I have seen patients who do not even need CAR T right now, but [are] on the waiting list in case the disease does not respond to the standard-of-care treatment, Dr. Ganguly says. This way, he adds, the patients are already in the system so the referring doctor picks up the phone and we get them quickly, and we get the CAR T hub activated, and we transition the patient through the whole process.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Siddhartha Ganguly is aMultiple Myeloma Specialist at the University of Kansas. Read More

Theres a rapid expansion going on in CAR T cell therapy, the remarkable living drug treatment that involves genetically engineering a patients own immune cells to fight cancer.

As of right now, CAR T cell therapy is approved by the U.S. Food and Drug Administration (FDA) for widespread use in:

You will be seeing many more diseases where the CAR T will become commercially available, Dr. Ganguly says, adding that patients with cancers that do not fall into the two FDA approval categories may still be able to access the treatment by enrolling in clinical trials.

Multiple myeloma is on of these diseases, as MD Andersons Robert Orlowski has previously told SurvivorNet.

Clinical trials which the FDA requires before it can approve a treatment are abundant in CAR T cell therapy. At Dr. Gangulys cancer center alone, he shares that at this moment there are 38 different trials taking place.

Because CAR T cell therapy is a highly specialized, intense procedure, its important to discuss the possibility of a referral with your oncologist.

When a patient is diagnosed with difficult-to-control lymphoma [for example], they should be referred to a center that is equipped with cellular therapeutics and technology, Dr. Ganguly says, adding that, right now at least, most of these specialized centers are located at academic institutions.

If your oncologist gives you a referral to one of these specialized centers, you will then meet with a cellular therapeutics specialist to discuss the next steps.

CAR T cell therapy is a highly technical treatment that carries the risk of several serious side effects, which explains why it requires a team of specialized professionals to administer.

Id say a village is required to take care of one patient [undergoing CAR T cell therapy], Dr. Ganguly says, adding that in his own institution, this village or team of specialists is collectively referred to as a CAR T hub. The team of specialists includes, among others:

So its a big team approach where holistically we take care of the patients and we take them through the whole process of identification to insurance approval trial accrual, collection of the cells, Dr. Ganguly says. And then post-treatment, taking care of the patient is also vitally important.

Originally, Dr. Ganguly says, there were only 16 centers in the country that had the expertise and experience to administer CAR T cell therapy. Now, however, that number is expanding.

With the explosion of CAR T, more and more centers are now involved in cellular therapeutics, he says. But we have a lot of work to do. There are a lot of patients that could benefit from this novel, exciting technology. But the knowledge is very important.

The knowledge that Dr. Ganguly references meaning the awareness that CAR T cell therapy is even an option in the first place, and the know-how needed to find a center offering it is not always a given. Thats why specialists are working hard to bring this knowledge to community oncologists.

We need to go to the grassroots, he says. We need to go to community oncologists and educate and talk about this technology so that the patients who are in dire need of this technique should be promptly referred.

The types of cancers that can benefit from CAR T cell therapy are often aggressive, fast-growing cancers, making it extremely important that oncologists refer their patients promptly in the cases where CAR T cell therapy is an option.

These cancers dont wait, Dr. Ganguly says. They grow exponentially, and sometimes, if we cannot get them on time, then the CAR T cannot be manufactured, and valuable time may be lost.

The importance of timing with CAR T cell therapy occasionally prompts patients to consider the option even before they need it, so that if and when they do need it, they will have access right away.

Sometimes, I have seen patients who do not even need CAR T right now, but [are] on the waiting list in case the disease does not respond to the standard-of-care treatment, Dr. Ganguly says. This way, he adds, the patients are already in the system so the referring doctor picks up the phone and we get them quickly, and we get the CAR T hub activated, and we transition the patient through the whole process.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Siddhartha Ganguly is aMultiple Myeloma Specialist at the University of Kansas. Read More

Read this article:
CAR T Cell Therapy Where and How to Access the Lifesaving Living Drug - SurvivorNet

Posted in Cell Therapy | Comments Off on CAR T Cell Therapy Where and How to Access the Lifesaving Living Drug – SurvivorNet

Car T-cell therapy: The future fifth pillar of cancer treatment – The Irish Times

Posted: March 4, 2020 at 10:46 pm

Revolutionary Car T-cell therapy is set to become the fifth pillar of cancer treatment and is already showing dramatic results in the successful treatment of blood cancers.

Prof Owen Smith is a consultant paediatric haematologist who has dedicated his 35-year career to researching and treating cancer in children and young adolescents. Smith, who is based at Childrens Health Ireland at Crumlin hospital, is a specialist in stem cell transplantation. Over the years, he has seen big advances in cancer treatments but few have excited him as much as Car T-cell therapy which is showing huge potential as a pioneering treatment for blood and other challenging cancers.

In a nutshell, Car (chimeric antigen receptor) T-cell therapy is a form of immunotherapy that uses the patients own immune cells to recognise and attack cancer. It involves drawing blood from the patient, isolating the T-cells within it and genetically altering and multiplying them in a lab. The end product is transfused back into the patient where the Car T-cells bind to an antigen or structural molecule on the cancer cells and kills them.

Car T-cells or Cars for short, are like sniper fire that target the cancer rather than blanket bombing it, explains Prof Smith. They cause much less toxicity than chemotherapy and have much better results and remission rates.

Cars therapy has been in gestation since the early 1980s with the first-generation treatment becoming available around 2010.

To date, about 2,200 Cars have been completed in the US, while in Europe the number is about 800 and growing fast. There are now two second generation Car T products licensed for three types of blood cancer and Prof Smith says: We now have hope with these relapse/refractory blood cancers where only a few years ago, we had none.

Prof Smith was working in Royal Free Hospital in London (one of the UKs major Car T therapy centres today) in the 1980s when the therapeutic potential of T-cells, which was initially discovered in Israel, was first being realised. It became clear through some good connected thinking that it was the T-cells that were having a very important effect on cure in patients with CML (chronic myeloid leukaemia), he says. Around the same time there were papers coming in from the States with similar results so the concept was beginning to gather momentum.

The question became: could you take T-cells from a donor and give them to people who were relapsing and put them into remission? Things began to crystallise in the late 80s/early 90s as T cells were recognised as immune effector cells that were very good at killing cancer, especially in patients with CML who were relapsing after stem cell transplantation.

Then people began wondering if we could use the end of the molecule the so-called antigen binding part of an antibody and link it to the T-cell receptor and put it into T-cells to see if that would give an even better result. What eventually followed between 2010 and 2014 were a number of first generation Car T-cell studies that showed it was very effective in some patients with haematological malignancies and in those with acute lymphoblastic and chronic lymphocytic leukaemia in particular. Since then there have been 10 big studies with second generation Cars that have also proved its efficacy, says Prof Smith.

Acute lymphoblastic leukaemia is the most common form of blood cancer in children and Prof Smith sees about 50 cases a year here. Unfortunately, if this cancer relapses, particularly during or shortly after chemotherapy, it usually becomes resistant to further treatment and the children can also no longer tolerate it. The only option up to now has been palliative care, but Cars is a lifeline that can alter this outcome.

Second generation Car T-cell activity can push around 90 per cent of children into remission and once you get them into remission you have time to get them into prime clinical condition to give them a stem cell transplant and cure them that way, says Prof Smith. In the adult population, about 20 cases a year of non-Hodgkins lymphoma would be suitable for this therapy.

Weve known for a long time that the immune system is important in someone developing cancer, Prof Smith adds. So, for example when a persons T-cells are knocked out by something like HIV, they typically have an increased risk of developing lymphoid malignancies. The immune system can also be tricked into not recognising when a cancer develops and undergoes metastatic spread. This immune activation therapy can unmask this camouflaging of the cancer resulting in regression.

One of the challenges with the Cars is that they can become lost in the body and lose their persistence. When this happens the person usually relapses. We are now looking at different combinations of Cars and using two or three of them on the one cell to prevent relapse, says Prof Smith.

This is a massively evolving field and one of these exponential technologies you hear about from time to time. Whats really encouraging it that its now being pushed out to treat other types of high-risk solid tumours that currently have dismal survival rates such as metastatic non-small cell lung cancer, pancreatic cancer, triple negative breast cancer, ovarian cancer, brain tumours and neuroblastomas in children. Its opening up a totally different treatment pathway for cancer.

Prof Smith acknowledges that Cars, like many innovative cancer treatments, is expensive at about 300,000 per commercially produced treatment. But he points out that as its use becomes more widespread prices will drop and that if the total costs of conventional treatments are added up the economic argument for its use is compelling. Yes, its costly but some recent health economic data from the USA is suggesting it may not be as costly as it first appears, he says. Specifically, repeated chemotherapy, the cost of regular hospital admissions due to relapse, trips to intensive care, blood product support and anti-bacterial, anti-fungal and anti-viral therapies all with very little return in terms of clinical outcome.

Prof Smith adds that Car T therapy is set to become the fifth pillar of cancer treatment alongside surgery, chemotherapy, radiation and targeted therapy and that whats happening now is just the start of the Car T revolution. The next phase will be using them in combination with checkpoint inhibitors (another arm of immunotherapy) and the third generation of Cars will have greater efficacy and less toxicity, he says.

Prof Smith is low key about his personal achievements but in addition to saving the lives of countless children under his care, he also has a distinguished research record and his work has been widely published and acknowledged internationally. He was to the forefront of a major breakthrough in the intervention and treatment of meningitis in the 1980s and he is a strong believer in robust peer-reviewed clinical trials, which he believes are one of the most effective ways of establishing a cure for any disease.

Owen Smith is professor of Paediatric and Adolescent Medicine at UCD, honorary Regius Professor of Physic (1637) at Trinity College and academic lead to the Childrens Hospital Group. He is also a principal investigator at the National Childrens Research Centre and Systems Biology Ireland at University College Dublin and national clinical programme lead for children and adolescents/young adults with cancer. In 2015 he was awarded a CBE by Queen Elizabeth for his life-long dedication to treating cancer in children.

Prof Smith is a speaker at the international BioPharma Ambition 2020 event which is being held in Dublin Castle on March 3rd and 4th.

Go here to read the rest:
Car T-cell therapy: The future fifth pillar of cancer treatment - The Irish Times

Posted in Cell Therapy | Comments Off on Car T-cell therapy: The future fifth pillar of cancer treatment – The Irish Times

Page 1,109«..1020..1,1081,1091,1101,111..1,1201,130..»